DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Dr Harriet Bell, House Officer, Auckland City Hospital, Auckland, New Zealand. DermNet NZ Editor in Chief: Adjunct A/Prof. Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. October 2019.
Alopecia is the medical term for hair loss. Alopecia is diffuse if it affects the scalp in general distribution. This is in contrast to localised or focal alopecia, which is characterised by patchy hair loss.
Diffuse alopecia is common, affecting up to 50% of men and women. While it can affect both sexes at any age, women present more frequently than men [1,2].
Hair follicles cycle through growing and resting phases.
Diffuse alopecia can be categorised into conditions that cause excessive hair shedding and conditions that cause hair thinning .
Abnormal hair shedding (or effluvium) may occur during the telogen or anagen phase of the hair cycle.
Telogen effluvium is the most common cause of diffuse hair shedding [3,5]. A triggering event causes an increased number of anagen hairs to prematurely enter the catagen and then telogen phase. Excessive shedding of telogen hairs occurs a few months after the triggering event .
Patients may notice clumps of hair falling out on their hairbrush or while showering . Up to 30–50% of scalp hair may be lost . The excess hair shedding may produce diffuse thinning or bitemporal recession .
Various triggers have been implicated in telogen effluvium; these include:
Anagen effluvium occurs when the anagen phase is interrupted, causing premature termination of hair growth and abrupt hair shedding.
Anagen effluvium is most commonly due to chemotherapy (see Drug-induced alopecia) and usually begins one to two weeks after treatment is started. It may result in 80–90% loss of body hair, including eyebrows and eyelashes [1,2]. It may also be caused by poisoning with thallium, colchicine or selenium .
Anagen effluvium may also be due to alopecia areata . Alopecia areata is an autoimmune condition in those with genetic predisposition and typically presents with bald patches (focal alopecia) [2,5]. Confluent or widespread alopecia areata presents with diffuse hair loss, sometimes resulting in complete baldness of the scalp (alopecia totalis) or total body hair loss (alopecia universalis) [1,2,5].
Gradual diffuse hair thinning is due to male or female pattern hair loss.
Diffuse hair thinning due to pattern hair loss is a gradual process [1,8].
Male pattern hair loss is caused by a genetic predisposition that affects the sensitivity of hair follicles to circulating androgens; for this reason, it is sometimes called androgenetic alopecia [1,4]. The characteristic pattern is a bitemporal recession and balding at the vertex and frontal regions.
Female pattern hair loss has a strong genetic component, but the role of androgens is unclear . The pattern is thinning over the top of the scalp with a widening of the midline part [1,4].
Pattern hair loss in females occurs earlier and more severely in polycystic ovary syndrome, with a virilising tumour, or on exposure to an exogenous androgen such as testosterone.
Pattern hair loss
Hair loss has minimal harmful physical effects; however, it may be psychologically damaging and negatively impact on the quality of life, as hair is linked with one’s identity (see Psychological effects of hair loss). Psychiatric disorders, including anxiety and depression, are more common in people with alopecia than in those without [6,9].
Diffuse alopecia is usually diagnosed clinically, with a detailed history and examination of the scalp. Additional tests may be used to confirm the diagnosis .
History may identify triggers or genetic susceptibility .
Laboratory workup should be performed to identify treatable causes. This may include:
The hair pull test involves grasping 40–60 closely grouped hairs and applying gentle traction. If more than 10% of hairs are easily pulled out, the test is positive .
For a trichogram, 20–50 hairs are plucked and then analysed under a microscope to estimate the percentages of anagen and telogen hairs.
An optimal skin biopsy of the scalp comprises two four-millimetre punch biopsies from the vertex of the scalp .
The treatment and prognosis of diffuse alopecia depend on the underlying cause.
Acute telogen effluvium resolves within three to six months and hair density returns to normal providing ongoing triggers or causative medications (see Drug-induced alopecia) have been identified and discontinued . Treatment is not usually necessary .
Hair shedding that lasts longer than six months is known as chronic telogen effluvium. It tends to fluctuate over some years, then usually resolves spontaneously .
Anagen effluvium is managed with observation and support .
Diffuse alopecia areata is challenging to treat. Even when treatment induces an increase in hair growth, hair loss may recur when treatment is stopped .
The natural course of diffuse alopecia areata is variable. One-third of patients recover spontaneously within six months, and 50–80% of these patients have persisting hair after a year. Some patients may have repeated episodes of diffuse alopecia areata [4,9].
The new hair that grows back may not be the same colour or texture as it was before it was lost .
The prognosis is worse for alopecia areata that is severe at its onset. Less than 10% of patients with alopecia totalis and alopecia universalis will recover .
Treatments for pattern alopecia should be continued indefinitely, as discontinuation results in recurring hair loss [4,6]. Treatments include:
Hair transplantation can be used to treat advanced male or female pattern hair loss .
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.